Video
Dr. Steinberg on Trial of HS-410 Vaccine in Bladder Cancer
Author(s):
Gary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer (NMIBC).
Gary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer (NMIBC).
In this phase II randomized trial, patients who were either BCG-naïve or recurrent with or without carcinoma in situ (CIS) received 1 of 2 doses of HS-410 (either 106 or 107cells/dose) or placebo. This was in combination with 6 weeks of induction BCG, followed by HS-410 for 6 more weeks.
HS-410 is compromised of an allogeneic cell line which is selected for high expression from bladder tumor antigens. It was found to be well tolerated and immunologic responses are consistent.
According to Steinberg, this vaccine shows promise as a potential treatment for NMIBC.
